← Eichor
Condition: Relapsed Refractory Systemic Lupus Erythematosus Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Relapsed Refractory Systemic Lupus Erythematosus

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT06980597Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT07246096Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06428188CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06978647CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06941129Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT06946485Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06614270A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06653556Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Phase 1 · 2 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07236801A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflamm
Phase 1 · 5 location(s) · Nanjing Legend Biotech Co. · NCT07331272A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · CytoCares Inc · NCT07193810An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT07174843UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06920433Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06350110Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07361094A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07123519An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07236762Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
NA · 1 location(s) · Tongji Hospital · NCT06902844CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
EARLY_Phase 1 · 1 location(s) · He Huang · NCT06785519A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Therorna · NCT07413341Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07490041
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.